COMPARE · Data as of August 28, 2026
CTRE vs MPT
Verdict: Side-by-side breakdown using the Bull Rankings model. CTRE scored 81.0, MPT scored 67.0 — CTRE leads.
Compare another set
Different reporting periods. CTRE's fundamentals are as of June 2026, but MPT's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
CTRE
CareTrust REIT, Inc.
69.4Fin
$39.03 · $9.2B
fundamentals as of
Strength gap
0.4
CTRE leads
MPT
Medical Properties Trust, Inc.
69Fin
$4.09 · $2.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthCTRE+61.8%
- Strongest balance sheetCTRE0.72
Side by side · every name on one set of axes
Fundamentals, head-to-head
CTRE
MPT
4.0%B+
Yield
8.8%A-
+61.8%A
Rev
-2.4%D+
0.72B+
D/E
2.16C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
CTRECareTrust REIT, Inc.
Why now
REIT - Healthcare Facilities · market cap $9.2b. 11% off the 52-week high of $43.62. Revenue growing +62% — in hypergrowth territory. 13 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $45.38 (implying +16% upside).
Moat
Net margin 62% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma.
Risk
P/S 16.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
MPTMedical Properties Trust, Inc.
Why now
REIT - Healthcare Facilities · market cap $2.4b. Down 37% from 52-week high of $6.47 — deep drawdown territory. 7 sell-side analysts rate this a Hold with a mean 1-yr target of $5.11 (implying +25% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
D/E 2.16 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -2.7%) — path to GAAP profitability is the core thesis risk. Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.